The CE Mark confirms that the Axonics product meets all of the essential requirements of the European Medical Device Directive for Active Implantable Medical Devices and enables Axonics to market its SNM System throughout the European Union.
Axonics has also received ethics committee approval from select centers in Western Europe and will start a 65-patient post-market clinical follow up (PMCF) study.
The Company also announced that Neurourology and Urodynamics published the results of a peer-reviewed study titled, “Cost Profiles and Budget Impact of Rechargeable Versus Non-Rechargeable Sacral Neuromodulation Devices in the Treatment of Overactive Bladder Syndrome.” The study assesses the potential cost impact to U.S. healthcare payers of a rechargeable SNM system. Findings determined that compared to non-rechargeable SNM systems for the treatment of OAB, a rechargeable SNM system with a long-lived battery could save the U.S. healthcare system more than $12 billion over the next 15 years. Physicians and researchers collaborating on the study included Karen L. Noblett, MD, University of California, Riverside; Roger R. Dmochowski, MD, Vanderbilt University; Sandip P. Vasavada, MD, Cleveland Clinic, and Abigail M. Garner, MS; Shan Liu, PhD; Jan B. Pietzsch, PhD of Wing Tech, Inc., Menlo Park, CA.
“The Axonics device promises increased patient comfort given its small size. Moreover, the fact that it is rechargeable and can function three times longer in patients will eliminate the need for repeat surgeries that are currently required every four or five years to replace implanted devices with drained batteries,” said Prof. Karen L. Noblett, M.D., Chair of the Department of Obstetrics and Gynecology, University of California Riverside School of Medicine. “Our economic study findings clearly show the Axonics System has the ability to also lower healthcare costs. This potentially allows more patients to benefit from a therapy that has been proven over many years to improve the quality of life of patients suffering from urinary and fecal dysfunction.”
OAB affects an estimated 85 million adults in the US and Europe. Another 40 million are reported to suffer from fecal incontinence. SNM therapy is an effective and durable treatment that has been widely used and reimbursed in Europe and the US for the past two decades. Over 200,000 patients have benefited from the therapy to date. SNM is the only OAB treatment with proven clinical superiority to standard medical therapy and OAB patients who receive SNM report significantly higher quality of life than patients undergoing drug treatment.
“Axonics has successfully developed a unique product to deliver SNM therapy that we believe will greatly improve the patient and clinician experience,” said Raymond W. Cohen, Axonics’ Chief Executive Officer. “We look forward to treating patients in our upcoming PMCF study.”
More details can be found from Axonics website.
No comments:
Post a Comment